Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,621 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predicting pathological upstaging after radical nephroureterectomy in patients with upper tract urothelial carcinoma: results from a multicenter cohort study.
Yamaguchi R, Kagawa H, Yoshihara K, Yamamoto S, Hara S, Miyajima K, Enei Y, Fukuokaya W, Iwatani K, Imai Y, Atsuta M, Mori K, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Ishii G, Higuchi T, Sato S, Yamada Y, Furuta A, Shimomura T, Kimura T, Miki J, Urabe F. Yamaguchi R, et al. Among authors: yamamoto s. Transl Androl Urol. 2024 Nov 30;13(11):2384-2395. doi: 10.21037/tau-24-357. Epub 2024 Nov 27. Transl Androl Urol. 2024. PMID: 39698572 Free PMC article.
Extracellular vesicles and prostate cancer management: a narrative review.
Urabe F, Yamada Y, Yamamoto S, Tsuzuki S, Kimura S, Ochiya T, Kimura T. Urabe F, et al. Among authors: yamamoto s. Transl Androl Urol. 2024 Mar 31;13(3):442-453. doi: 10.21037/tau-23-533. Epub 2024 Mar 20. Transl Androl Urol. 2024. PMID: 38590964 Free PMC article. Review.
Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective study.
Muramoto K, Urabe F, Koike Y, Yamamoto S, Suzuki H, Miyajima K, Fukuokaya W, Iwatani K, Imai Y, Igarashi T, Mori K, Aikawa K, Kimura S, Tashiro K, Yamada Y, Sasaki T, Sato S, Yuen SKK, Shimomura T, Furuta A, Tsuzuki S, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Muramoto K, et al. Among authors: yamamoto s. Urol Oncol. 2024 Oct;42(10):332.e21-332.e32. doi: 10.1016/j.urolonc.2024.04.001. Epub 2024 May 9. Urol Oncol. 2024. PMID: 38729868
Does age impact clinical outcomes of radical nephroureterectomy in the elderly?-results from a multicenter retrospective study.
Ishikawa M, Muramoto K, Yoshihara K, Yamamoto S, Miyajima K, Iwatani K, Imai Y, Kayano S, Ito K, Igarashi T, Mori K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Yamada Y, Sasaki T, Sato S, Shimomura T, Furuta A, Miki J, Urabe F, Kimura T. Ishikawa M, et al. Among authors: yamamoto s. Transl Androl Urol. 2024 May 31;13(5):688-698. doi: 10.21037/tau-24-37. Epub 2024 May 22. Transl Androl Urol. 2024. PMID: 38855598 Free PMC article.
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Fukuokaya W, Yanagisawa T, Hashimoto M, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Miki J, Oyama Y, Abe H, Kimura T. Fukuokaya W, et al. Among authors: yamamoto s. Cancer Immunol Immunother. 2023 Apr;72(4):841-849. doi: 10.1007/s00262-022-03291-5. Epub 2022 Sep 14. Cancer Immunol Immunother. 2023. PMID: 36102985 Free PMC article.
Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Hashimoto M, Fukuokaya W, Yanagisawa T, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Oyama Y, Abe H, Miki J, Kimura T. Hashimoto M, et al. Among authors: yamamoto s. Int J Clin Oncol. 2024 May;29(5):612-619. doi: 10.1007/s10147-024-02482-7. Epub 2024 Mar 2. Int J Clin Oncol. 2024. PMID: 38430304
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study.
Urabe F, Imai Y, Goto Y, Tashiro K, Hashimoto M, Yoshihara K, Yamamoto S, Hara S, Miyajima K, Fukuokaya W, Enei Y, Iwatani K, Kayano S, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Tsuzuki S, Murakami M, Hata K, Shimomura T, Yamada H, Miki J, Kimura T. Urabe F, et al. Among authors: yamamoto s. Jpn J Clin Oncol. 2024 Nov 2;54(11):1208-1213. doi: 10.1093/jjco/hyae098. Jpn J Clin Oncol. 2024. PMID: 39037966
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H. Uchimoto T, et al. Among authors: yamamoto s. BJU Int. 2023 Apr;131(4):477-485. doi: 10.1111/bju.15893. Epub 2022 Sep 26. BJU Int. 2023. PMID: 36098556
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival.
Nakamori K, Yamazaki S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Ohno T, Yano Y, Nishimura K, Tokushige S, Uchimoto T, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H. Nakamori K, et al. Among authors: yamamoto s. Clin Transl Radiat Oncol. 2022 Dec 10;39:100558. doi: 10.1016/j.ctro.2022.12.001. eCollection 2023 Mar. Clin Transl Radiat Oncol. 2022. PMID: 36545361 Free PMC article.
10,621 results
You have reached the last available page of results. Please see the User Guide for more information.